Progression of squamous cell carcinoma is regulated by miR-139-5p/CXCR4

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• MicroRNA-139-5p (miR-139-5p) is recognized for its tumor suppressor roles in various cancers.
• CXCR4 is implicated in cancer progression and metastasis.
• The specific roles of miR-139-5p and CXCR4 in oral squamous cell carcinoma (OSCC) require further elucidation.

Purpose of the Study:

• To investigate the expression patterns of miR-139-5p and CXCR4 in OSCC.
• To elucidate the functional relationship and mechanism of action between miR-139-5p and CXCR4 in OSCC.
• To assess the therapeutic potential of targeting miR-139-5p in OSCC.

Main Methods:

• Quantitative real-time PCR (qRT-PCR) to measure miR-139-5p and CXCR4 expression in OSCC tissues and cell lines.
• In vitro assays (proliferation, migration) and in vivo xenograft models to evaluate the functional impact of miR-139-5p.
• Western blotting to assess the expression of downstream targets (c-myc, cyclinD1, Bcl-2).
• Luciferase reporter assays to confirm direct binding of miR-139-5p to CXCR4 mRNA.

Main Results:

• miR-139-5p was significantly downregulated, while CXCR4 was upregulated in OSCC tissues and cells compared to normal controls.
• Low miR-139-5p expression correlated with poorer patient survival.
• Overexpression of miR-139-5p suppressed OSCC cell proliferation and migration in vitro and in vivo.
• miR-139-5p overexpression reduced the expression of WNT-responsive genes c-myc, cyclinD1, and Bcl-2.
• These inhibitory effects were reversed by miR-139-5p inhibition or CXCR4 overexpression.
• Direct binding of miR-139-5p to the 3' UTR of CXCR4 mRNA was confirmed, indicating negative regulation.

Conclusions:

• miR-139-5p functions as a tumor suppressor in OSCC by directly targeting and downregulating CXCR4.
• The miR-139-5p/CXCR4 axis plays a critical role in regulating OSCC cell proliferation, migration, and survival.
• Restoration of miR-139-5p may represent a potential therapeutic strategy for OSCC.